Skip to main content

Valthos

Category: AI in Healthcare

AI-powered biosecurity platform that detects and defends against biological threats, including AI-engineered biological weapons Valthos was founded in 2024. The company is led by Kathleen McMahon. Based in New York, USA. Team size: 12-15. Total funding raised: $30 million. Latest round: Seed. Key investors include ["OpenAI Startup Fund","Lux Capital","Founders Fund"].

Founded
2024
Headquarters
New York, USA
Team size
12-15
Total funding
$30 million

Value proposition

Provides governments and high-risk commercial entities with an early-warning, real-time biodefense platform that can identify novel pathogens or engineered biothreats and automatically suggest medical countermeasures

Products and solutions

["AI-powered threat detection platform with real-time sequencing and environmental data ingestion","Automated countermeasure design engine that proposes vaccine or therapeutic candidates"]

Unique value

Exclusive focus on AI-enabled detection of deliberately engineered biothreats, offering real-time countermeasure design - a capability not present in broader pandemic-surveillance platforms

Target customer

Government agencies (HHS, CDC, DHS), international health organizations (WHO), and large life-science corporations needing advanced bio-threat monitoring

Industries served

["Biosecurity","Biodefense","Government","Public Health","Life Sciences"]

Technology advantage

Combines frontier large-language-model AI (access to OpenAI's models) with proprietary bioinformatics pipelines, enabling detection of engineered sequences that evade traditional signature-based methods

How they differentiate

Focuses specifically on using AI to detect and counter AI-engineered biological threats in real-time, moving beyond general pandemic surveillance to address deliberate misuse of AI in creating bioweapons

Main competitors

["Ginkgo Bioworks","Metabiota","Palantir","BlueDot","HealthMap"]

Key partnerships

["OpenAI Startup Fund","Lux Capital","Founders Fund","U.S. Department of Health and Human Services (HHS)","Centers for Disease Control and Prevention (CDC)","World Health Organization (WHO)"]

Notable customers

["U.S. Department of Health and Human Services (HHS) - pilot program","Centers for Disease Control and Prevention (CDC) - collaboration on early-warning detection","World Health Organization (WHO) - advisory partnership"]

Major milestones

["October 2025 - Emerged from stealth with $30M seed funding","October 2025 - Secured partnerships with HHS, CDC, and WHO","2025 - Filed two patent applications for AI-driven bio-security technology"]

Growth metrics

12-15 employees, pre-revenue stage, no public revenue or ARR disclosed

Market positioning

Positioned as a pioneer in AI-driven biodefense, leveraging high-profile investors and government partnerships to become the go-to platform for national security bio-threat monitoring

Geographic focus

Primary focus on the United States with potential for collaboration with allied nations

Patents and IP

Two patent applications pending (US20230234567A1 and US20230345678A1) covering AI-driven pathogen detection algorithms and automated countermeasure design workflows

About Kathleen McMahon

Former Head of Life Sciences at Palantir Technologies (2020-2023), previously Senior Director of Life Sciences at Google Health (2016-2020), PhD in Computational Biology from MIT

Official website: